arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ELI LILLY & Co

LLY
$1172.14 ▲ +7.09 (+0.61%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
75 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
70
Health
Good
Moderately Bullish
auto_awesome

Analytical Summary

ELI LILLY & Co demonstrates solid fundamentals with strength in Return on Common Equity (%). However, watch Debt to Equity which shows concerning trends. Overall, the data suggests a moderately positive outlook with manageable risks.

Market Cap $1.0T
Dividend Yield 0.30%
Revenue Growth 47.7%
Op. Margin
ROIC
FCF / Share $11.98
Trailing P/E 147.4x
Price / Book 30.9x
FCF Yield 1.0%
Debt / Equity 1.41
info Valuation on last close. End-of-day price, Sep 22, 2026.

75-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$22.97B
↑ +47.7%
Net Income Profit after all expenses
$7.09B
↑ +25.3%
FCF / Share Free cash flow per share
$11.98
↑ +100.9%
Long-Term Debt Long-term obligations
$47.86B
↑ +21.6%
trending_up

Bullish Indicators

  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
91
Returns
99
Financial Health
17
Cash Quality
55

Dividend History

Dividend / share · sourced from SEC filings
$6.23 Latest / share
+15.4% YoY
+14.4% 9-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 20 years · 75 quarters